## CLAIMS

**1.** Use of a protein or polypeptide comprising a polypeptide that has at least 75 % sequence identity with the amino acid sequence SEQ ID NO: 1 in the manufacture of a medicament for treating and/or preventing a disease or condition associated with platelet recruitment, neutrophil recruitment, neutrophil activation and/or neutrophil extracellular trap formation (NETosis).

**2.** The use according to claim 1, wherein said protein or polypeptide comprises a polypeptide having the amino acid sequence SEQ ID NO: 1.

**3.** The use according to claim 1 or claim 2, wherein inhibiting platelet recruitment, neutrophil recruitment, neutrophil activation and/or NETosis treats and/or prevents a disease or condition associated with platelet recruitment, neutrophil recruitment, neutrophil activation and/or NETosis.

**4.** The use according to claim 3, wherein said disease or condition associated with platelet recruitment, neutrophil recruitment, neutrophil activation and/or NETosis is selected from the group comprising venous thrombosis, arterial thrombosis, thromboinflammation, and cardiovascular diseases.

**5.** The use according claim 3 or 4, wherein said disease or condition associated with platelet recruitment, neutrophil recruitment, neutrophil activation and/or NETosis is thromboinflammation.

**6.** The use according to claim 5, wherein said thromboinflammation is selected from the group comprising atherosclerosis, plaque rupture, devices-induced thromboinflammation, thrombosis induced by catheterism and/or stent positioning procedures, thrombosis induced by extracorporeal circulation, thrombus formation following cerebral injuries, coronary artery disease, acute myocardial infraction, cancer-associated thrombosis, metastasis-associated thrombosis, stroke-associated thrombosis, Behçet's disease (BD), antineutrophil cytoplasmic antibody-associated (ANCA) vasculitides, Takayasu arteritis, rheumatoid arthritis, systemic lupus erythematosus, antiphospholipid syndrome, familial Mediterranean fever,

thromboangiitis obliterans (TAO), sepsis, inflammatory bowel diseases, heparin-induced thrombocytopenia, immunothrombosis, thrombosis associated with preeclampsia, thrombotic complication in cell and cell cluster transplantation and in whole organ transplantation or grafts, venous thromboembolism, aneurysms, and skeletal muscle ischemia-reperfusion syndrome.

**7.** The use according to claim 6, wherein said thrombinflammation is immunothrombosis.

**8.** The use according to claim 6, wherein said thromboinflammation is atherosclerosis.

**9.** The use according to claim 6, wherein said thromboinflammation is thrombosis induced by catheterism and/or stent positioning procedures.

**10.** The use according to claim 6, wherein said thromboinflammation is blood contacting medical devices-induced thromboinflammation.

**11.** The use according to claim 6, wherein said thromboinflammation is plaque rupture.

**12.** The use according to claim 6, wherein said thromboinflammation is thrombosis associated with the extracorporeal circulation.

**13.** A pharmaceutical composition comprising a protein or polypeptide comprising a polypeptide that has at least 75 % sequence identity with the amino acid sequence SEQ ID NO: 1 and at least one pharmaceutically acceptable excipient when used in the use defined by any one of claims 1 to 12.

**14.** A medical device coated with an isolated polypeptide that has at least 75 % sequence identity with the amino acid sequence SEQ ID NO: 1 when used in the use defined by any one of claims 1 to 12.

**15.** A kit comprising a protein or polypeptide comprising an isolated polypeptide that has at least 75 % sequence identity with the amino acid sequence SEQ ID NO: 1 when used in the use defined by any one of claims 1 to 12.